NCT06605586View on ClinicalTrials.gov

Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2030

Conditions
Myelofibrosis
Interventions
DRUG

Tasquinimod

treatment with tasquinimod capsules once daily

Trial Locations (6)

Unknown

NOT_YET_RECRUITING

DE-Aachen-UKAACHEN, Aachen

NOT_YET_RECRUITING

NL-Amsterdam-AmsterdamUMC, Amsterdam

NOT_YET_RECRUITING

NL-Groningen-UMCG, Groningen

RECRUITING

NL-Nijmegen-RADBOUDUMC, Nijmegen

NOT_YET_RECRUITING

NL-Rotterdam-ERASMUSMC, Rotterdam

NOT_YET_RECRUITING

NL-Utrecht-UMCUTRECHT, Utrecht

All Listed Sponsors
lead

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER